tirzepatide clinical trial enrollment An Observational Study of Cardiovascular Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists Tirzepatide for the Treatment of

The Federal Drug Administration has approved two GLPs for weight loss: semaglutide, which is sold under the brand names "Ozempic" and "Wegovy," and mounjaro and liraglutide, which are sold under the brand name "Saxenda." These drugs are injectable medications that were originally approved by the FDA in 2014

The rising popularity of GLP-1 receptor agonists like semaglutide and tirzepatide has sparked growing interest among both patients and medical professionals seeking effective solutions for weight loss and metabolic health

Hallow KM, Gebremichael Y, Helmlinger G, Vallon V

Market Dynamics Zepbound, approved in late 2023 for chronic weight management, is structurally similar to Lillys diabetes drug Mounjaro but marketed separately for weight loss

A.AxsonS